Content area

|
|

Basalcellekarcinom

Forfatter(e)
Martin Glud, Silje Haukali Omland & Robert Gniadecki Dermato-Venerologisk Afdeling, Bispebjerg Hospital Ugeskr Læger 2016;178:V07150603
Reference: 
Ugeskr Læger 2016;178:V07150603
Blad nummer: 
Sidetal: 
2-6
Basal cell carcinoma surgery
Basal cell carcinoma (BCC) is the most common type of cancer in humans. The lifetime risk of developing BCC is 30%. The scope of the treatment is total eradication of the tumour followed by preservation of functionality and optimal cosmetic results. The risk of recurrence after treatment is highest in the tumours with aggressive growth patterns, in tumours located in the facial H-zone and in recurrent tumours. The optimal treatment of high-risk BCCs is surgical excision or radiotherapy. Low-risk tumours may be treated with cryotherapy, curettage, photodynamic therapy or topical agents.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Camilla Bang | 29/11
2 kommentarer
af Stine Madsen-Østerbye | 29/11
1 Kommentar
af Kaj Seidelin | 29/11
6 kommentarer
af Pedram Kazemi-Esfarjani | 28/11
2 kommentarer
af Ulf Bern Jensen | 24/11
2 kommentarer
af Bodil Marie Nielsen | 24/11
2 kommentarer
af Toke Seierøe Barfod | 23/11
2 kommentarer
af Thorkild I.A. Sørensen | 20/11
1 Kommentar
af Kim Varming | 20/11
1 Kommentar